Safety and Immunogenicity of the HPV-16/18 AS04-Adjuvanted Vaccine: A Randomized, Controlled Trial in Adolescent Girls

Journal of Adolescent Health

Volumn 46, Issue 5, 2010, Pages 414-421

  Rivera Medina, Doris M ^a   Valencia, Alejandra ^b   de Velasquez, Alet ^c   Huang, Li Min ^d   Prymula, Roman ^e   García Sicilia, Jose ^f   Rombo, Lars ^g,h   David, Marie Pierre P ⁱ   Descamps, Dominique ⁱ   Hardt, Karin ⁱ   Dubin, Gary ^j  

^a Organización Para El Desarrollo y la Investigación Salud en Honduras   (Honduras)

^b HOSPITAL UNIVERSITARIO FUNDACIÓN SANTA FE DE BOGOTÁ   (Colombia)

^c Policlínica Santiago Barraza   (Panama)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e UNIVERSITY OF DEFENCE   (Czech Republic)

^f HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^g KAROLINSKA INSTITUTE   (Sweden)

^h Sormland County Council   (Sweden)

ⁱ GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^j GLAXOSMITHKLINE   (United States)

more..

Author keywords

Adolescent; Cervical cancer; Girls; Human papillomavirus; Immunogenicity; Safety; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; ANTIGEN; HEPATITIS A VACCINE; HPV 16/18 AS04 ADJUVANTED VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY; WART VIRUS VACCINE;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA NERVOSA; ANTIBODY TITER; APPENDICITIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE THYROIDITIS; AUTOMUTILATION; BRONCHITIS; CHILD; CHRONIC DISEASE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONCUSSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; COXSACKIE VIRUS INFECTION; DEHYDRATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSMENORRHEA; DYSPNEA; EARDRUM PERFORATION; ENTEROBIASIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; FEVER; GASTRITIS; GASTROENTERITIS; GEOMETRY; GUNSHOT INJURY; HEPATITIS A; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNIZATION; IMMUNOGENICITY; INCIDENCE; LUDWIG ANGINA; LYMPHADENITIS; MAJOR CLINICAL STUDY; MASTOIDITIS; MIGRAINE WITH AURA; MULTICENTER STUDY; MYALGIA; OVARY CYST; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PSEUDOCROUP; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SEROCONVERSION; SEROLOGY; SIDE EFFECT; SUICIDE ATTEMPT; SYMPTOM; SYNCOPE; TREATMENT DURATION; ULNA FRACTURE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA; UTERINE CERVIX CANCER; VIRAL GASTROENTERITIS; VIRUS LIKE AGENT;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; EUROPE; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 77950873078     PISSN: 1054139X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jadohealth.2010.02.006     Document Type: Article

References (18)

1. Walboomers J.M., Jacobs M.V., Manos M.M., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189 (1999) 12-19
2. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
3. Muñoz N., Bosch F.X., De Sanjosé S., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348 (2003) 518-527
4. Bosch F.X., Burchell A.N., Schiffman M., et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 26 Suppl 10 (2008) K1-K16
5. Brown D.R., Shew M.L., Qadadri B., et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis 191 (2005) 182-192
6. Moscicki A.B. HPV infections in adolescents. Dis Markers 23 (2007) 229-234
7. Collins S., Mazloomzadeh S., Winter H., et al. High incidence of cervical human papillomavirus infection in women during their first sexual relationship. BJOG 109 (2002) 96-98
8. Harper D.M., Franco E.L., Wheeler C.M., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomized controlled trial. Lancet 364 (2004) 1757-1765
9. Harper D.M., Franco E.L., Wheeler C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomized control trial. Lancet 367 (2006) 1247-1255
10. Paavonen J., Jenkins D., Bosch F.X., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomized controlled trial. Lancet 369 (2007) 2161-2170
11. Paavonen J., Naud P., J Salmerón J., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomized study in young women. Lancet 374 (2009) 301-314
12. GlaxoSmithKline Vaccine HPV-007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: Analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 374 (2009) 1975-1985
13. Pedersen C., Petaja T., Strauss G., et al. Immunization of adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 40 (2007) 564-571
14. Descamps D., Hardt K., Spiessens B., et al. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials. Hum Vaccin 5 (2009) 332-340
15. Verstraeten T., Descamps D., David M.P., et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine 26 (2008) 6630-6638
16. Garçon N., Chomez P., and Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: Concepts, achievements and perspectives. Expert Rev Vaccines 6 (2007) 723-739
17. Giannini S.L., Hanon E., Moris P., et al. Enhanced humoral and memory B cell immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24 (2006) 5937-5949
18. David M.P., Van Herck K., Hardt K., et al. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses. Gynecol Oncol 115 3 Suppl (2009) S1-S6